Clinical Trial Update: Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating vorapaxar as add-on antiplatelet therapy in patients with and without diabetes mellitus in the setting of myocardial infarction, comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Myocardial Infarction
• Peripheral Arterial Disease

Drugs mentioned

• Vorapaxar (vorapaxar)

Snippet

Sponsor: University of Florida | Conditions: Myocardial Infarction, Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2020-01-27